IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer
Authors:
Open Access
- 4 April 2026
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a poor survival rate and limited treatments. Agonistic CD40 antibodies are promising, but clinical trials have shown only modest efficacy and significant hepatotoxicity. We previously reported that IL-1 pathway blockade enhances CD40 agonist efficacy against melanoma by depleting polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs; CD11b+Ly6C+Ly6G+). Because PMN-MDSCs also cause liver toxicity, we investigated the impact of IL-1R1 blockade on the efficacy and toxicity of agonistic CD40 antibody therapy in PDAC. Agonistic CD40 antibody therapy induced immune activation and significantly prolonged survival in orthotopic PDAC-bearing mice. The combination of an agonistic CD40 antibody and IL-1R1 blockade upregulated multiple immune-related pathways and enhanced innate and adaptive responses. However, it did not further improve CD40 efficacy or reduce liver toxicity. The efficacy of the CD40 agonist was partially dependent on CD8⁺ T cells. Our findings underscore the complex role of IL-1 signaling in modulating immune responses in PDAC and caution against pursuing IL-1R1 blockade, either as monotherapy or combined with agonistic CD40 antibodies, in clinical trials for PDAC.Keywords
Funding Information
- Hirshberg Foundation for Pancreatic Cancer Research
This publication has 40 references indexed in Scilit:
- The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinomaNeoplasia, 2022
- The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiotaCell Reports Medicine, 2021
- Neutrophil diversity and plasticity in tumour progression and therapyNature Reviews Cancer, 2020
- Pancreatic cancerThe Lancet, 2020
- Immunotherapy for pancreatic cancer: A 2020 updateCancer Treatment Reviews, 2020
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitorsNature Medicine, 2020
- Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brainNature Communications, 2017
- Tumor‐induced CD11b+ Gr‐1+ myeloid‐derived suppressor cells exacerbate immune‐mediated hepatitis in mice in a CD40‐dependent mannerEuropean Journal of Immunology, 2015
- Inflammation and cancer: An ancient link with novel potentialsInternational Journal of Cancer, 2007
- ROLE OF P38 MAPK, AP-1, AND NF-κB IN INTERLEUKIN-1β-INDUCED IL-8 EXPRESSION IN HUMAN VASCULAR SMOOTH MUSCLE CELLSCytokine, 2002